Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Glaxo, Pfizer to Merge Consumer Health Units, Form New JV

Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.

Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates

Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.

Gilead's (GILD) Harvoni and Descovy Get Approval in China

Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know

In the latest trading session, GlaxoSmithKline (GSK) closed at $38.34, marking a -0.7% move from the previous day.

Gilead (GILD) Announces Data on CAR T Therapy Candidate

Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

Company News For Dec 4, 2018

Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

Glaxo (GSK) announces definitive deal to buy TESARO.

TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.

Glaxo to Sell India's Popular Horlicks Brand to Unilever

Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.

Indrajit Bandyopadhyay headshot

Key Pharma Players With HIV Focus Ahead of World Aids Day

We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.

Merck (MRK) Receives Approval for 2 HIV Medicines in EU

Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

Novartis (NVS) Receives EC Approval for Neulasta Biosimilar

Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.

What Makes GlaxoSmithKline (GSK) a Strong Momentum Stock: Buy Now?

Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In

Per a Financial Times report, Glaxo (GSK) is in exclusive talks with Unilever to sell its Horlicks brand in India. Another report in an India-based newspaper says Nestle is close to buying Horlicks.

Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease

AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.

3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far

Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.

Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan

GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.

Glaxo Inks Marketing Deal for Anaemia Candidate in Japan

GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth

Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

Let???s see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs

FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs

FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz

The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

Gilead's Vemlidy Gets Approval in China for HBV Infection

Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.